Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Understanding of molecular events in cancer requires proteome-level characterisation. Here, proteome profiling of patient samples representing primary and progressed prostate cancer enables the authors to identify pathway alterations that are not reflected at the genomic and transcriptomic levels.

Bibliographic Details
Main Authors: Leena Latonen, Ebrahim Afyounian, Antti Jylhä, Janika Nättinen, Ulla Aapola, Matti Annala, Kati K. Kivinummi, Teuvo T. L. Tammela, Roger W. Beuerman, Hannu Uusitalo, Matti Nykter, Tapio Visakorpi
Format: Article
Language:English
Published: Nature Publishing Group 2018-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-03573-6

Internet

https://doi.org/10.1038/s41467-018-03573-6

Similar Items